India, Nov. 4 -- uniQURE N.V. (QURE), a gene therapy company, on Wednesday reported financial results for the third quarter, noting a lower loss as revenues increased mildly and income tax payments declined.
The company has been developing gene therapies for rare genetic diseases and gained approval from the U.S. Food and Drug Administration (FDA) for a hemophilia B treatment. Drugs currently in the pipeline include therapies for Huntington's disease, refractory temporal lobe epilepsy, and Fabry disease.
Q3 Financial Highlights:
Net loss for the third quarter amounted to $61.22 million or $0.88 per share, while in the same period of 2025, the company reported a profit of $80.53 million or $1.38 per share.
This may be attributable to an ...